{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:38:59Z","timestamp":1793162339716,"version":"4.5.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008725","name":"Instytut Farmakologii, Polskiej Akademii Nauk","doi-asserted-by":"publisher","award":["Statutory Funds"],"award-info":[{"award-number":["Statutory Funds"]}],"id":[{"id":"10.13039\/501100008725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Depression is a highly prevalent mood disorder and one of the major health concerns in modern society. Moreover, it is characterized by a high prevalence of coexistence with many other diseases including metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity. Currently used antidepressant drugs, which mostly target brain monoaminergic neurotransmission, have limited clinical efficacy. Although the etiology of depression has not been fully elucidated, current scientific data emphasize the role of neurotrophic factors deficiencies, disturbed homeostasis between the nervous system and the immune and endocrine systems, as well as disturbances in brain energy metabolism and dysfunctions in the gut-brain axis as important factors in the pathogenesis of this neuropsychiatric disorder. Therefore, therapeutic options that could work in a way other than classic antidepressants are being sought to increase the effectiveness of the treatment. Interestingly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), used in the treatment of T2DM and obesity, are known to show pro-cognitive and neuroprotective properties, and exert modulatory effects on immune, endocrine and metabolic processes in the central nervous system. This review article discusses the potential antidepressant effects of GLP-1RAs, especially in the context of their action on the processes related to neuroprotection, inflammation, stress response, energy metabolism, gut-brain crosstalk and the stability of the gut microbiota.<\/jats:p>\n                <jats:p><jats:bold>Graphic abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s43440-021-00274-8","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T07:02:25Z","timestamp":1621321345000},"page":"1020-1032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression"],"prefix":"10.1007","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9866-5777","authenticated-orcid":false,"given":"Jan","family":"Detka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"G\u0142ombik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"274_CR1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0140-6736(07)61414-7","volume":"370","author":"PS Wang","year":"2007","unstructured":"Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Borges G, Bromet EJ, et al. Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. Lancet. 2007;370:841\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(07)61414-7.","journal-title":"Lancet"},{"key":"274_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/npp.2013.342","volume":"39","author":"C Belzung","year":"2014","unstructured":"Belzung C. Innovative drugs to treat depression\u202f: did animal models fail to be predictive or did clinical trials fail to detect effects\u202f? Neuropsychopharmacology. 2014;39:1041\u201351. https:\/\/doi.org\/10.1038\/npp.2013.342.","journal-title":"Neuropsychopharmacology"},{"key":"274_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1056\/NEJM198808183190706","volume":"319","author":"PW Gold","year":"1988","unstructured":"Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression Relation to the neurobiology of stress (2). N Engl J Med. 1988;319:413\u201320. https:\/\/doi.org\/10.1056\/NEJM198808183190706.","journal-title":"N Engl J Med"},{"key":"274_CR4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.pnpbp.2010.04.011","volume":"35","author":"PA Zunszain","year":"2011","unstructured":"Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:722\u20139. https:\/\/doi.org\/10.1016\/j.pnpbp.2010.04.011.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"274_CR5","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","volume":"392","author":"GS Malhi","year":"2018","unstructured":"Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299\u2013312. https:\/\/doi.org\/10.1016\/S0140-6736(18)31948-2.","journal-title":"Lancet"},{"key":"274_CR6","doi-asserted-by":"publisher","first-page":"e0165267","DOI":"10.1371\/journal.pone.0165267","volume":"11","author":"D Setoyama","year":"2016","unstructured":"Setoyama D, Kato TA, Hashimoto R, Kunugi H, Hattori K, Hayakawa K, et al. Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients-a multicenter pilot analysis. PLoS ONE. 2016;11:e0165267. https:\/\/doi.org\/10.1371\/journal.pone.0165267.","journal-title":"PLoS ONE"},{"key":"274_CR7","doi-asserted-by":"publisher","first-page":"e00536","DOI":"10.1002\/prp2.536","volume":"7","author":"H Akimoto","year":"2019","unstructured":"Akimoto H, Tezuka K, Nishida Y, Nakayama T, Takahashi Y, Asai S. Association between use of oral hypoglycemic agents in Japanese patients with type 2 diabetes mellitus and risk of depression: a retrospective cohort study. Pharmacol Res Perspect. 2019;7:e00536. https:\/\/doi.org\/10.1002\/prp2.536.","journal-title":"Pharmacol Res Perspect"},{"key":"274_CR8","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2174\/1570159x14666160229114755","volume":"14","author":"Y Bansal","year":"2016","unstructured":"Bansal Y, Kuhad A. Mitochondrial dysfunction in depression. Curr Neuropharmacol. 2016;14:610\u20138. https:\/\/doi.org\/10.2174\/1570159x14666160229114755.","journal-title":"Curr Neuropharmacol"},{"key":"274_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/ejn.14631","volume":"53","author":"AS Carlessi","year":"2021","unstructured":"Carlessi AS, Borba LA, Zugno AI, Quevedo J, R\u00e9us GZ. Gut microbiota-brain axis in depression: the role of neuroinflammation. Eur J Neurosci. 2021;53:222\u201335. https:\/\/doi.org\/10.1111\/ejn.14631.","journal-title":"Eur J Neurosci"},{"key":"274_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0347-4","author":"K Semenkovich","year":"2015","unstructured":"Semenkovich K, Brown ME, Svrakic DM, Lustman PJ. Depression in type 2 diabetes mellitus\u202f: prevalence, impact, and treatment. Drugs. 2015. https:\/\/doi.org\/10.1007\/s40265-015-0347-4.","journal-title":"Drugs"},{"key":"274_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0017-5","author":"Y Milaneschi","year":"2019","unstructured":"Milaneschi Y, Simmons WK, Van REFC, Wjh B. Depression and obesity\u202f: evidence of shared biological mechanisms. Mol Psychiatry. 2019. https:\/\/doi.org\/10.1038\/s41380-018-0017-5.","journal-title":"Mol Psychiatry"},{"key":"274_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, Alessio DD, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010.","journal-title":"Mol Metab"},{"key":"274_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/dom.12591","volume":"18","author":"M Nauck","year":"2016","unstructured":"Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18:203\u201316. https:\/\/doi.org\/10.1111\/dom.12591.","journal-title":"Diabetes Obes Metab"},{"key":"274_CR14","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. NN8022\u20134180 trial investigators. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382:2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1916038.","journal-title":"N Engl J Med."},{"key":"274_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/23312025.2016.1229086","volume":"311","author":"MK Holt","year":"2016","unstructured":"Holt MK, Trapp S. The physiological role of the brain GLP-1 system in stress. Cogent Biol. 2016;311:1\u20139. https:\/\/doi.org\/10.1080\/23312025.2016.1229086.","journal-title":"Cogent Biol"},{"key":"274_CR16","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.3390\/nu12113304","volume":"12","author":"Y Diz-Chaves","year":"2020","unstructured":"Diz-Chaves Y, Herrera-P\u00e9rez S, Gonz\u00e1lez-Mat\u00edas LC, Lamas JA, Mallo F. Glucagon-like peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress. Nutrients. 2020;12:3304. https:\/\/doi.org\/10.3390\/nu12113304.","journal-title":"Nutrients"},{"key":"274_CR17","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2165\/11635890-000000000-00000","volume":"26","author":"C H\u00f6lscher","year":"2012","unstructured":"H\u00f6lscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs. 2012;26:871\u201382. https:\/\/doi.org\/10.2165\/11635890-000000000-00000.","journal-title":"CNS Drugs"},{"key":"274_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40263-018-0593-6","volume":"33","author":"AF Batista","year":"2019","unstructured":"Batista AF, Bodart V, De FFG, Ferreira ST. Neuroprotective actions of glucagon-like peptide-1 (glp-1) analogues in alzheimer\u2019s and parkinson\u2019s diseases. CNS Drugs. 2019;33:209\u201323. https:\/\/doi.org\/10.1007\/s40263-018-0593-6.","journal-title":"CNS Drugs"},{"key":"274_CR19","doi-asserted-by":"publisher","DOI":"10.1515\/hmbci-2018-0031","author":"MA Camkurt","year":"2018","unstructured":"Camkurt MA, Lavagnino L, Zhang XY, Teixeira AL. Liraglutide for psychiatric disorders: clinical evidence and challenges. Horm Mol Biol Clin Investig. 2018. https:\/\/doi.org\/10.1515\/hmbci-2018-0031.","journal-title":"Horm Mol Biol Clin Investig."},{"key":"274_CR20","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3389\/fphar.2020.01270","volume":"11","author":"YK Kim","year":"2020","unstructured":"Kim YK, Kim OY, Song J. Alleviation of Depression by glucagon-like peptide 1 Through the regulation of neuroinflammation, neurotransmitters, neurogenesis, and synaptic function. Front Pharmacol. 2020;11:1270. https:\/\/doi.org\/10.3389\/fphar.2020.01270.","journal-title":"Front Pharmacol"},{"key":"274_CR21","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409\u201339. https:\/\/doi.org\/10.1152\/physrev.00034.2006.","journal-title":"Physiol Rev"},{"key":"274_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3389\/fphar.2015.00264","volume":"6","author":"KJ Culhane","year":"2015","unstructured":"Culhane KJ, Liu Y, Cai Y, Yan EC. Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors. Front Pharmacol. 2015;6:264. https:\/\/doi.org\/10.3389\/fphar.2015.00264.","journal-title":"Front Pharmacol"},{"key":"274_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature22394","volume":"546","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Sun B, Feng D, Hu H, Chu M, Qu Q, et al. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nat Publ Gr. 2017;546:248\u201353. https:\/\/doi.org\/10.1038\/nature22394.","journal-title":"Nat Publ Gr"},{"key":"274_CR24","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","volume":"84","author":"DJ Drucker","year":"1987","unstructured":"Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA. 1987;84:3434\u20138. https:\/\/doi.org\/10.1073\/pnas.84.10.3434.","journal-title":"Proc Natl Acad Sci USA"},{"key":"274_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","volume":"128","author":"NK Smith","year":"2019","unstructured":"Smith NK, Hackett TA, Galli A, Flynn CR. GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Neurochem Int. 2019;128:94\u2013105. https:\/\/doi.org\/10.1016\/j.neuint.2019.04.010.","journal-title":"Neurochem Int"},{"key":"274_CR26","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1210\/endo.140.3.6550","volume":"140","author":"C Montrose-Rafizadeh","year":"1999","unstructured":"Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, Yang H, et al. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology. 1999;140:1132\u201340. https:\/\/doi.org\/10.1210\/endo.140.3.6550.","journal-title":"Endocrinology"},{"key":"274_CR27","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","volume":"137","author":"BP Bullock","year":"1996","unstructured":"Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137:2968\u201378. https:\/\/doi.org\/10.1210\/endo.137.7.8770921.","journal-title":"Endocrinology"},{"key":"274_CR28","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"C Pyke","year":"2014","unstructured":"Pyke C, Heller RS, Kirk RK, \u00d8rskov C, Reedtz-Runge S, Kaastrup P, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280\u201390. https:\/\/doi.org\/10.1210\/en.2013-1934.","journal-title":"Endocrinology"},{"key":"274_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1210\/en.2014-1675","volume":"156","author":"KM Heppner","year":"2015","unstructured":"Heppner KM, Kirigiti M, Secher A, Paulsen SJ, Buckingham R, Pyke C, et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology. 2015;156:255\u201367. https:\/\/doi.org\/10.1210\/en.2014-1675.","journal-title":"Endocrinology"},{"key":"274_CR30","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1365-2982.2009.01317.x","volume":"21","author":"V Bucinskaite","year":"2009","unstructured":"Bucinskaite V, Tolessa T, Pedersen J, Rydqvist B, Zerihun L, Holst JJ, et al. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil. 2009;21:978-e78. https:\/\/doi.org\/10.1111\/j.1365-2982.2009.01317.x.","journal-title":"Neurogastroenterol Motil"},{"key":"274_CR31","doi-asserted-by":"publisher","first-page":"R885","DOI":"10.1152\/ajpregu.00520.2015","volume":"310","author":"SE Kanoski","year":"2016","unstructured":"Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310:R885-95. https:\/\/doi.org\/10.1152\/ajpregu.00520.2015.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"274_CR32","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","volume":"4","author":"SC Cork","year":"2015","unstructured":"Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab. 2015;4:718\u201331. https:\/\/doi.org\/10.1016\/j.molmet.2015.07.008.","journal-title":"Mol Metab"},{"key":"274_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.regpep.2004.08.026","volume":"128","author":"PJ Larsen","year":"2005","unstructured":"Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept. 2005;128:97\u2013107. https:\/\/doi.org\/10.1016\/j.regpep.2004.08.026.","journal-title":"Regul Pept"},{"key":"274_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cobeha.2016.02.005","volume":"9","author":"MR Hayes","year":"2016","unstructured":"Hayes MR, Schmidt HD. GLP-1 influences food and drug reward. Curr Opin Behav Sci. 2016;9:66\u201370. https:\/\/doi.org\/10.1016\/j.cobeha.2016.02.005.","journal-title":"Curr Opin Behav Sci"},{"key":"274_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00957-3","author":"NS Hernandez","year":"2020","unstructured":"Hernandez NS, Weir VR, Ragnini K, Merkel R, Zhang Y, Mace K, et al. GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA. Mol Psychiatry. 2020. https:\/\/doi.org\/10.1038\/s41380-020-00957-3.","journal-title":"Mol Psychiatry"},{"key":"274_CR36","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","volume":"236","author":"M Thomsen","year":"2019","unstructured":"Thomsen M, Holst JJ, Molander A, Linnet K, Ptito M, Fink-Jensen A. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology. 2019;236:603\u201311. https:\/\/doi.org\/10.1007\/s00213-018-5089-z.","journal-title":"Psychopharmacology"},{"key":"274_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.physbeh.2019.03.026","volume":"206","author":"NS Hernandez","year":"2019","unstructured":"Hernandez NS, Schmidt HD. Physiology & Behavior Central GLP-1 receptors\u202f: novel molecular targets for cocaine use disorder. Physiol Behav. 2019;206:93\u2013105. https:\/\/doi.org\/10.1016\/j.physbeh.2019.03.026.","journal-title":"Physiol Behav"},{"key":"274_CR38","doi-asserted-by":"publisher","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","volume":"267","author":"J Eng","year":"1992","unstructured":"Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267:7402\u20135 (PMID: 1313797).","journal-title":"J Biol Chem."},{"key":"274_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","volume":"27","author":"AJ Kastin","year":"2003","unstructured":"Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord. 2003;27:313\u20138. https:\/\/doi.org\/10.1038\/sj.ijo.0802206.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"274_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2202-13-33","volume":"13","author":"K Hunter","year":"2012","unstructured":"Hunter K, H\u00f6lscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33. https:\/\/doi.org\/10.1186\/1471-2202-13-33.","journal-title":"BMC Neurosci"},{"key":"274_CR41","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/ijo.2015.136","volume":"39","author":"M Christensen","year":"2015","unstructured":"Christensen M, Sparre-Ulrich AH, Hartmann B, Grevstad U, Rosenkilde MM, Holst JJ, et al. Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. Int J Obes (Lond). 2015;39:1651\u20134. https:\/\/doi.org\/10.1038\/ijo.2015.136.","journal-title":"Int J Obes (Lond)"},{"key":"274_CR42","doi-asserted-by":"publisher","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","volume":"5","author":"S Gabery","year":"2020","unstructured":"Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-R\u00f8nne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5:e133429. https:\/\/doi.org\/10.1172\/jci.insight.133429.","journal-title":"JCI Insight"},{"key":"274_CR43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5498\/wjp.v2.i3.49","volume":"2","author":"G Serafini","year":"2012","unstructured":"Serafini G. Neuroplasticity and major depression, the role of modern antidepressant drugs. World J Psychiatry. 2012;2:49\u201357. https:\/\/doi.org\/10.5498\/wjp.v2.i3.49.","journal-title":"World J Psychiatry"},{"key":"274_CR44","doi-asserted-by":"publisher","first-page":"6871089","DOI":"10.1155\/2017\/6871089","volume":"2017","author":"W Liu","year":"2017","unstructured":"Liu W, Ge T, Leng Y, Pan Z, Fan J, Yang W, Cui R. The role of neural plasticity in depression: from hippocampus to prefrontal cortex. Neural Plast. 2017;2017:6871089. https:\/\/doi.org\/10.1155\/2017\/6871089.","journal-title":"Neural Plast"},{"key":"274_CR45","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm919","volume":"9","author":"MJ During","year":"2003","unstructured":"During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9:1173\u20139. https:\/\/doi.org\/10.1038\/nm919.","journal-title":"Nat Med"},{"key":"274_CR46","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jad.2018.12.112","volume":"246","author":"W Liu","year":"2019","unstructured":"Liu W, Liu J, Huang Z, Cui Z, Li L, Liu W, et al. Possible role of GLP-1 in antidepressant effects of metformin and exercise in CUMS mice. J Affect Disord. 2019;246:486\u201397. https:\/\/doi.org\/10.1016\/j.jad.2018.12.112.","journal-title":"J Affect Disord"},{"key":"274_CR47","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1523\/JNEUROSCI.2904-18.2019","volume":"39","author":"J Zemdegs","year":"2019","unstructured":"Zemdegs J, Martin H, Pintana H, Bullich S, Manta S, Marqu\u00e9s MA, et al. Metformin promotes anxiolytic and antidepressant-like responses in insulin-resistant mice by decreasing circulating branched-chain amino acids. J Neurosci. 2019;39:5935\u201348. https:\/\/doi.org\/10.1523\/JNEUROSCI.2904-18.2019.","journal-title":"J Neurosci"},{"key":"274_CR48","doi-asserted-by":"publisher","first-page":"4727390","DOI":"10.1155\/2020\/4727390","volume":"16","author":"T Nguyen","year":"2020","unstructured":"Nguyen T, Gong M, Wen S, Yuan X, Wang C, Jin J, et al. The Mechanism of metabolic influences on the endogenous GLP-1 by oral antidiabetic medications in type 2 diabetes mellitus. J Diabetes Res. 2020;16:4727390. https:\/\/doi.org\/10.1155\/2020\/4727390.","journal-title":"J Diabetes Res"},{"key":"274_CR49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.brainres.2018.04.031","volume":"1694","author":"H Weina","year":"2018","unstructured":"Weina H, Yuhu N, Christian H, Birong L, Feiyu S, Le W. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity. Brain Res. 2018;1694:55\u201362. https:\/\/doi.org\/10.1016\/j.brainres.2018.04.031.","journal-title":"Brain Res"},{"key":"274_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04910-8","author":"TS Trammell","year":"2020","unstructured":"Trammell TS, Henderson NL, Madkour HS, Stanwood GD, Graham DL. GLP-1R activation alters performance in cognitive tasks in a sex-dependent manner. Neurol Sci. 2020. https:\/\/doi.org\/10.1007\/s10072-020-04910-8.","journal-title":"Neurol Sci"},{"key":"274_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1385\/NMM:5:1:011","volume":"5","author":"RS Duman","year":"2004","unstructured":"Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med. 2004;5:11\u201325. https:\/\/doi.org\/10.1385\/NMM:5:1:011.","journal-title":"Neuromolecular Med"},{"key":"274_CR52","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1001\/archpsyc.60.8.804","volume":"60","author":"Y Dwivedi","year":"2003","unstructured":"Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003;60:804\u201315. https:\/\/doi.org\/10.1001\/archpsyc.60.8.804.","journal-title":"Arch Gen Psychiatry"},{"key":"274_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2015.09.035","volume":"1634","author":"C Ji","year":"2016","unstructured":"Ji C, Xue GF, Lijun C, Feng P, Li D, Li L, Li G, H\u00f6lscher C. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson\u2019s disease by increasing expression of BNDF. Brain Res. 2016;1634:1\u201311. https:\/\/doi.org\/10.1016\/j.brainres.2015.09.035.","journal-title":"Brain Res"},{"key":"274_CR54","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.biopha.2018.10.066","volume":"109","author":"A Gomes","year":"2019","unstructured":"Gomes A, Souza D, Jos\u00e9 A, Chaves M, Victor J, Oliveira S, et al. Biomedicine & pharmacotherapy prevention of pentylenetetrazole-induced kindling and behavioral comorbidities in mice by levetiracetam combined with the GLP-1 agonist liraglutide\u202f: involvement of brain antioxidant and BDNF upregulating properties. Biomed Pharmacother. 2019;109:429\u201339. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.066.","journal-title":"Biomed Pharmacother"},{"key":"274_CR55","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.3389\/fpsyg.2018.02201","volume":"9","author":"Y Liu","year":"2018","unstructured":"Liu Y, Zhao J, Guo W. Emotional roles of mono-aminergic neurotransmitters in major depressive disorder and anxiety disorders. Front Psychol. 2018;9:2201. https:\/\/doi.org\/10.3389\/fpsyg.2018.02201.","journal-title":"Front Psychol"},{"key":"274_CR56","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/s0006-8993(01)03379-0","volume":"929","author":"AA Owji","year":"2002","unstructured":"Owji AA, Khoshdel Z, Sanea F, Panjehshahin MR, Shojaee Fard M, Smith DM, et al. Effects of intracerebroventricular injection of glucagon like peptide-1 and its related peptides on serotonin metabolism and on levels of amino acids in the rat hypothalamus. Brain Res. 2002;929:70\u20135. https:\/\/doi.org\/10.1016\/s0006-8993(01)03379-0.","journal-title":"Brain Res"},{"key":"274_CR57","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2337\/db14-0668","volume":"64","author":"SV Korol","year":"2015","unstructured":"Korol SV, Jin Z, Babateen O, Birnir B. GLP-1 and exendin-4 transiently enhance GABAA receptor-mediated synaptic and tonic currents in rat hippocampal CA3 pyramidal neurons. Diabetes. 2015;64:79\u201389. https:\/\/doi.org\/10.2337\/db14-0668.","journal-title":"Diabetes"},{"key":"274_CR58","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ijo.2010.59","volume":"34","author":"V Gault","year":"2010","unstructured":"Gault V, Porter W, Flatt P, et al. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. Int J Obes. 2010;34:1341\u20134. https:\/\/doi.org\/10.1038\/ijo.2010.59.","journal-title":"Int J Obes"},{"key":"274_CR59","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11011-008-9118-1","volume":"24","author":"M Maes","year":"2009","unstructured":"Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 2009;24:27\u201353. https:\/\/doi.org\/10.1007\/s11011-008-9118-1.","journal-title":"Metab Brain Dis"},{"key":"274_CR60","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1177\/0269881117711708","volume":"31","author":"P Kopschina Feltes","year":"2017","unstructured":"Kopschina Feltes P, Doorduin J, Klein HC, Ju\u00e1rez-Orozco LE, Dierckx RA, Moriguchi-Jeckel CM, et al. Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. J Psychopharmacol. 2017;31:1149\u201365. https:\/\/doi.org\/10.1177\/0269881117711708.","journal-title":"J Psychopharmacol"},{"key":"274_CR61","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/ejn.14720","volume":"53","author":"R Troubat","year":"2021","unstructured":"Troubat R, Barone P, Leman S, Desmidt T, Cressant A, Atanasova B, et al. Neuroinflammation and depression: a review. Eur J Neurosci. 2021;53:151\u201371. https:\/\/doi.org\/10.1111\/ejn.14720.","journal-title":"Eur J Neurosci"},{"key":"274_CR62","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1210\/en.2011-1895","volume":"153","author":"K Velmurugan","year":"2012","unstructured":"Velmurugan K, Balamurugan AN, Loganathan G, Ahmad A, Hering BJ, Pugazhenthi S. Antiapoptotic actions of exendin-4 against hypoxia and cytokines are augmented by CREB. Endocrinology. 2012;153:1116\u201328. https:\/\/doi.org\/10.1210\/en.2011-1895.","journal-title":"Endocrinology"},{"key":"274_CR63","doi-asserted-by":"publisher","first-page":"104615","DOI":"10.1016\/j.phrs.2019.104615","volume":"152","author":"G Yoon","year":"2020","unstructured":"Yoon G, Kim Y, Song J. Glucagon-like peptide-1 suppresses neuroin flammation and improves neural structure. Pharmacol Res. 2020;152:104615. https:\/\/doi.org\/10.1016\/j.phrs.2019.104615.","journal-title":"Pharmacol Res"},{"key":"274_CR64","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12974-019-1638-6","volume":"16","author":"Y Shan","year":"2019","unstructured":"Shan Y, Tan S, Lin Y, Liao S, Zhang B, Chen X, et al. The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke. J Neuroinflammation. 2019;16:242. https:\/\/doi.org\/10.1186\/s12974-019-1638-6.","journal-title":"J Neuroinflammation"},{"key":"274_CR65","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1073\/pnas.1914655117","volume":"117","author":"KA Dudek","year":"2020","unstructured":"Dudek KA, Dion-Albert L, Lebel M, LeClair K, Labrecque S, Tuck E, et al. Molecular adaptations of the blood-brain barrier promote stress resilience vs depression. Proc Natl Acad Sci USA. 2020;117:3326\u201336. https:\/\/doi.org\/10.1073\/pnas.1914655117.","journal-title":"Proc Natl Acad Sci USA"},{"key":"274_CR66","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","volume":"31","author":"PL McClean","year":"2011","unstructured":"McClean PL, Parthsarathy V, Faivre E, H\u00f6lscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J Neurosci. 2011;31:6587\u201394. https:\/\/doi.org\/10.1523\/JNEUROSCI.0529-11.2011.","journal-title":"J Neurosci"},{"key":"274_CR67","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3233\/JPD-171068","volume":"7","author":"F Ventorp","year":"2017","unstructured":"Ventorp F, Bay-Richter C, Nagendra AS, Janelidze S, Matsson VS, Lipton J, et al. Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines. J Parkinsons Dis. 2017;7:263\u201373. https:\/\/doi.org\/10.3233\/JPD-171068.","journal-title":"J Parkinsons Dis"},{"key":"274_CR68","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.psyneuen.2008.12.012","volume":"34","author":"M Szyma\u0144ska","year":"2009","unstructured":"Szyma\u0144ska M, Budziszewska B, Jaworska-Feil L, Basta-Kaim A, Kubera M, Le\u015bkiewicz M, Regulska M, Laso\u0144 W. The effect of antidepressant drugs on the HPA axis activity, glucocorticoid receptor level and FKBP51 concentration in prenatally stressed rats. Psychoneuroendocrinology. 2009;34:822\u201332. https:\/\/doi.org\/10.1016\/j.psyneuen.2008.12.012.","journal-title":"Psychoneuroendocrinology"},{"key":"274_CR69","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.yebeh.2013.10.020","volume":"38","author":"MF Juruena","year":"2014","unstructured":"Juruena MF. Early-life stress and HPA axis trigger recurrent adulthood depression. Epilepsy Behav. 2014;38:148\u201359. https:\/\/doi.org\/10.1016\/j.yebeh.2013.10.020.","journal-title":"Epilepsy Behav"},{"key":"274_CR70","first-page":"343","volume":"54","author":"B Budziszewska","year":"2002","unstructured":"Budziszewska B. Effect of antidepressant drugs on the hypothalamic-pituitary-adrenal axis activity and glucocorticoid receptor function. Pol J Pharmacol. 2002;54:343\u20139 (PMID: 12523487).","journal-title":"Pol J Pharmacol"},{"key":"274_CR71","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/10253890.2017.1369523","volume":"20","author":"MG Oyola","year":"2017","unstructured":"Oyola MG, Handa RJ. Hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes: sex differences in regulation of stress responsivity. Stress. 2017;20:476\u201394. https:\/\/doi.org\/10.1080\/10253890.2017.1369523.","journal-title":"Stress"},{"key":"274_CR72","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0006-8993(03)03117-2","volume":"985","author":"S Sarkar","year":"2003","unstructured":"Sarkar S, Fekete C, L\u00e9gr\u00e1di G\u00c1, Lechan RM. Glucagon like peptide-1 (7\u201336) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res. 2003;985:163\u20138. https:\/\/doi.org\/10.1016\/S0006-8993(03)03117-2.","journal-title":"Brain Res"},{"key":"274_CR73","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.mce.2012.06.023","volume":"362","author":"K Kageyama","year":"2012","unstructured":"Kageyama K, Yamagata S, Akimoto K, Sugiyama A, Murasawa S, Suda T. Action of glucagon-like peptide 1 and glucose levels on corticotropin-releasing factor and vasopressin gene expression in rat hypothalamic 4B cells. Mol Cell Endocrinol. 2012;362:221\u20136. https:\/\/doi.org\/10.1016\/j.mce.2012.06.023.","journal-title":"Mol Cell Endocrinol"},{"key":"274_CR74","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.bbrc.2014.07.116","volume":"451","author":"K Katsurada","year":"2014","unstructured":"Katsurada K, Maejima Y, Nakata M, Kodaira M, Suyama S. Biochemical and Biophysical Research Communications Endogenous GLP-1 acts on paraventricular nucleus to suppress feeding\u202f: Projection from nucleus tractus solitarius and activation of corticotropin-releasing hormone, nesfatin-1 and oxytocin neurons. Biochem Biophys Res Commun. 2014;451:276\u201381. https:\/\/doi.org\/10.1016\/j.bbrc.2014.07.116.","journal-title":"Biochem Biophys Res Commun"},{"key":"274_CR75","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.physbeh.2008.04.026","volume":"95","author":"KP Kinzig","year":"2008","unstructured":"Kinzig KP, Hargrave SL, Honors MA. Binge-type eating attenuates corticosterone and hypophagic responses to restraint stress. Physiol Behav. 2008;95:108\u201313. https:\/\/doi.org\/10.1016\/j.physbeh.2008.04.026.","journal-title":"Physiol Behav"},{"key":"274_CR76","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1210\/en.2009-0915","volume":"151","author":"M Gil-Lozano","year":"2010","unstructured":"Gil-Lozano M, P\u00e9rez-Tilve D, Alvarez-Crespo M, Mart\u00eds A, Fernandez AM, Catalina PAF, et al. GLP-1(7\u201336)-amide and exendin-4 stimulate the HPA axis in rodents and humans. Endocrinology. 2010;151:2629\u201340. https:\/\/doi.org\/10.1210\/en.2009-0915.","journal-title":"Endocrinology"},{"key":"274_CR77","doi-asserted-by":"publisher","unstructured":"Gil-Lozano M, Roman\u00ed-P\u00e9rez M, Outeiri\u00f1o-Iglesias V, Vigo E, Gonz\u00e1lez-Mat\u00edas LC, Brubaker PL, et al. Corticotropin-releasing hormone and the sympathoadrenal system are major mediators in the effects of peripherally administered exendin-4 on the hypothalamic-pituitary-adrenal axis of male rats. Endocrinology. 2014;155:2511\u201323. https:\/\/doi.org\/10.1210\/en.2013-1718","DOI":"10.1210\/en.2013-1718"},{"key":"274_CR78","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1210\/jc.2018-01420","volume":"104","author":"B Winzeler","year":"2019","unstructured":"Winzeler B, da Concei\u00e7\u00e3o I, Refardt J, Sailer CO, Dutilh G, Christ-Crain M. Effects of glucagon-like peptide-1 receptor agonists on hypothalamic-pituitary-adrenal axis in healthy volunteers. J Clin Endocrinol Metab. 2019;104:202\u20138. https:\/\/doi.org\/10.1210\/jc.2018-01420.","journal-title":"J Clin Endocrinol Metab"},{"key":"274_CR79","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.neuropharm.2018.01.048","volume":"136","author":"RB Mansur","year":"2018","unstructured":"Mansur RB, Lee Y, Subramaniapillai M, Brietzke E, Mcintyre RS. Neuropharmacology Cognitive dysfunction and metabolic comorbidities in mood disorders\u202f: A repurposing opportunity for glucagon-like peptide 1 receptor agonists\u202f? Neuropharmacology. 2018;136:335\u201342. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.048.","journal-title":"Neuropharmacology"},{"key":"274_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2015.02.014","volume":"460","author":"T Sato","year":"2015","unstructured":"Sato T, Hayashi H, Hiratsuka M, Hirasawa N. Glucocorticoids decrease the production of glucagon-like peptide-1 at the transcriptional level in intestinal L-cells. Mol Cell Endocrinol. 2015;460:1\u20138. https:\/\/doi.org\/10.1016\/j.mce.2015.02.014.","journal-title":"Mol Cell Endocrinol"},{"key":"274_CR81","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1042\/CS20140719","volume":"129","author":"C Kappe","year":"2015","unstructured":"Kappe C, Fransson L, Wolbert P, Orts\u00e4ter H. Glucocorticoids suppress GLP-1 secretion: possible contribution to their diabetogenic effects. Clin Sci (Lond). 2015;129:405\u201314. https:\/\/doi.org\/10.1042\/CS20140719.","journal-title":"Clin Sci (Lond)"},{"key":"274_CR82","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1073\/pnas.0808716106","volume":"106","author":"R Zhang","year":"2009","unstructured":"Zhang R, Packard BA, Tauchi M, D\u2019Alessio DA, Herman JP. Glucocorticoid regulation of preproglucagon transcription and RNA stability during stress. Proc Natl Acad Sci USA. 2009;106:5913\u20138. https:\/\/doi.org\/10.1073\/pnas.0808716106.","journal-title":"Proc Natl Acad Sci USA"},{"key":"274_CR83","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.pharep.2018.11.001","volume":"71","author":"J Detka","year":"2019","unstructured":"Detka J, Slusarczyk J, Kurek A, Kucharczyk M, Adamus T, et al. Hypothalamic insulin and glucagon-like peptide-1 levels in an animal model of depression and their effect on corticotropin-releasing hormone promoter gene activity in a hypothalamic cell line. Pharm Rep. 2019;71:338\u201346. https:\/\/doi.org\/10.1016\/j.pharep.2018.11.001.","journal-title":"Pharm Rep"},{"key":"274_CR84","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s12640-019-00131-w","volume":"37","author":"K G\u0142ombik","year":"2020","unstructured":"G\u0142ombik K, Detka J, G\u00f3ralska J, et al. Brain Metabolic Alterations in Rats Showing Depression-Like and Obesity Phenotypes. Neurotox Res. 2020;37:406\u201324. https:\/\/doi.org\/10.1007\/s12640-019-00131-w.","journal-title":"Neurotox Res"},{"key":"274_CR85","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/YCO.0000000000000376","volume":"31","author":"R Gaspersz","year":"2018","unstructured":"Gaspersz R, Nawijn L, Lamers F, Penninx BWJH. Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome. Curr Opin Psychiatry. 2018;31:17\u201325. https:\/\/doi.org\/10.1097\/YCO.0000000000000376.","journal-title":"Curr Opin Psychiatry"},{"key":"274_CR86","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.psyneuen.2015.11.021","volume":"65","author":"RH Anderberg","year":"2016","unstructured":"Anderberg RH, Richard JE, Hansson C, Nissbrandt H, Bergquist F, Skibicka KP. Psychoneuroendocrinology GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology. 2016;65:54\u201366. https:\/\/doi.org\/10.1016\/j.psyneuen.2015.11.021.","journal-title":"Psychoneuroendocrinology"},{"key":"274_CR87","doi-asserted-by":"publisher","first-page":"104720","DOI":"10.1016\/j.psyneuen.2020.104720","volume":"119","author":"L L\u00f3pez-Ferreras","year":"2020","unstructured":"L\u00f3pez-Ferreras L, Eerola K, Shevchouk OT, Richard JE, Nilsson FH, Jansson LE, et al. Psychoneuroendocrinology the supramammillary nucleus controls anxiety-like behavior; key role of GLP-1R. Psychoneuroendocrinology. 2020;119:104720. https:\/\/doi.org\/10.1016\/j.psyneuen.2020.104720.","journal-title":"Psychoneuroendocrinology"},{"key":"274_CR88","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3389\/fnins.2018.00386","volume":"12","author":"J Allen","year":"2018","unstructured":"Allen J, Romay-Tallon R, Brymer KJ, Caruncho HJ, Kalynchuk LE. Mitochondria and mood: mitochondrial dysfunction as a key player in the manifestation of depression. Front Neurosci. 2018;12:386. https:\/\/doi.org\/10.3389\/fnins.2018.00386.","journal-title":"Front Neurosci"},{"key":"274_CR89","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.2174\/092986711797379221","volume":"18","author":"D Marazziti","year":"2011","unstructured":"Marazziti D, Baroni S, Picchetti M, Landi P, Silvestri S, Vatteroni E, Catena DM. Mitochondrial alterations and neuropsychiatric disorders. Curr Med Chem. 2011;18:4715\u201321. https:\/\/doi.org\/10.2174\/092986711797379221.","journal-title":"Curr Med Chem"},{"issue":"Suppl 1","key":"274_CR90","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/jdi.12464","volume":"7","author":"K Katsurada","year":"2016","unstructured":"Katsurada K, Yada T. Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. J Diabetes Investig. 2016;7(Suppl 1):64\u20139. https:\/\/doi.org\/10.1111\/jdi.12464.","journal-title":"J Diabetes Investig."},{"key":"274_CR91","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.neuroscience.2015.03.046","volume":"295","author":"J Detka","year":"2015","unstructured":"Detka J, Kurek A, Kucharczyk M, G\u0142ombik K, Basta-Kaim A, Kubera M, et al. Brain glucose metabolism in an animal model of depression. Neuroscience. 2015;295:198\u2013208. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.03.046.","journal-title":"Neuroscience"},{"key":"274_CR92","doi-asserted-by":"publisher","first-page":"586939","DOI":"10.3389\/fnins.2020.586939","volume":"14","author":"K G\u0142ombik","year":"2020","unstructured":"G\u0142ombik K, Detka J, Kurek A, Budziszewska B. Impaired brain energy metabolism: involvement in depression and hypothyroidism. Front Neurosci. 2020;14:586939. https:\/\/doi.org\/10.3389\/fnins.2020.586939 (PMID:33343282).","journal-title":"Front Neurosci"},{"key":"274_CR93","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eplepsyres.2018.03.009","volume":"142","author":"R Wang","year":"2018","unstructured":"Wang R, Xue G, H\u00f6lscher C, Tian M, Feng P. Post-treatment with the GLP-1 analogue liraglutide alleviate chronic in flammation and mitochondrial stress induced by Status epilepticus. Epilepsy Res. 2018;142:45\u201352. https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.03.009.","journal-title":"Epilepsy Res"},{"key":"274_CR94","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1002\/jcp.29204","volume":"235","author":"W He","year":"2020","unstructured":"He W, Wang H, Zhao C, Tian X, Li L, Wang H. Role of liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke. J Cell Physiol. 2020;235:2986\u20133001. https:\/\/doi.org\/10.1002\/jcp.29204.","journal-title":"J Cell Physiol"},{"key":"274_CR95","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.cell.2016.07.028","volume":"166","author":"C Garc\u00eda-C\u00e1ceres","year":"2016","unstructured":"Garc\u00eda-C\u00e1ceres C, Quarta C, Varela L, Gao Y, Gruber T, Legutko B, et al. Astrocytic insulin signaling couples brain glucose uptake with nutrient availability. Cell. 2016;166:867\u201380. https:\/\/doi.org\/10.1016\/j.cell.2016.07.028.","journal-title":"Cell"},{"key":"274_CR96","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s42255-018-0031-6","volume":"1","author":"C Vicente-Gutierrez","year":"2019","unstructured":"Vicente-Gutierrez C, Bonora N, Bobo-Jimenez V, Jimenez-Blasco D, Lopez-Fabuel I, Fernandez E, et al. Astrocytic mitochondrial ROS modulate brain metabolism and mouse behaviour. Nat Metab. 2019;1:201\u201311. https:\/\/doi.org\/10.1038\/s42255-018-0031-6.","journal-title":"Nat Metab"},{"issue":"1189\u20131205","key":"274_CR97","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.cmet.2020.05.001","volume":"31","author":"K Timper","year":"2020","unstructured":"Timper K, Del R\u00edo-Mart\u00edn A, Cremer AL, Bremser S, Alber J, Giavalisco P, et al. GLP-1 Receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and function. Cell Metab. 2020;31(1189\u20131205):e13. https:\/\/doi.org\/10.1016\/j.cmet.2020.05.001.","journal-title":"Cell Metab"},{"key":"274_CR98","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1113\/jphysiol.2014.270850","volume":"592","author":"GJ Dockray","year":"2014","unstructured":"Dockray GJ. Gastrointestinal hormones and the dialogue between gut and brain. J Physiol. 2014;592:2927\u201341. https:\/\/doi.org\/10.1113\/jphysiol.2014.270850.","journal-title":"J Physiol"},{"key":"274_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2016.07.019","author":"JR Kelly","year":"2016","unstructured":"Kelly JR, Borre Y, Brien CO, Patterson E, Aidy S, Kennedy PJ, et al. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res. 2016. https:\/\/doi.org\/10.1016\/j.jpsychires.2016.07.019.","journal-title":"J Psychiatr Res"},{"key":"274_CR100","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1515\/revneuro-2017-0072","volume":"29","author":"G Winter","year":"2018","unstructured":"Winter G, Hart RA, Charlesworth RPG, Sharpley CF. Gut microbiome and depression: what we know and what we need to know. Rev Neurosci. 2018;29:629\u201343. https:\/\/doi.org\/10.1515\/revneuro-2017-0072.","journal-title":"Rev Neurosci"},{"key":"274_CR101","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/mp.2016.44","volume":"21","author":"P Zheng","year":"2016","unstructured":"Zheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host\u2019s metabolism. Mol Psychiatry. 2016;21:786\u201396. https:\/\/doi.org\/10.1038\/mp.2016.44.","journal-title":"Mol Psychiatry"},{"key":"274_CR102","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/1471-2180-14-189","volume":"14","author":"JD Galley","year":"2014","unstructured":"Galley JD, Nelson MC, Yu Z, et al. Exposure to a social stressor disrupts the community structure of the colonic mucosa-associated microbiota. BMC Microbiol. 2014;14:189. https:\/\/doi.org\/10.1186\/1471-2180-14-189.","journal-title":"BMC Microbiol"},{"issue":"9","key":"274_CR103","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1021\/acs.jproteome.6b00262","volume":"15","author":"A Aoki-Yoshida","year":"2016","unstructured":"Aoki-Yoshida A, Aoki R, Moriya N, Goto T, Kubota Y, Toyoda A, et al. Omics studies of the murine intestinal ecosystem exposed to subchronic and mild social defeat stress. J Proteome Res. 2016;15(9):3126\u201338. https:\/\/doi.org\/10.1021\/acs.jproteome.6b00262.","journal-title":"J Proteome Res"},{"key":"274_CR104","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1177\/0004867419877954","volume":"53","author":"AS McGovern","year":"2019","unstructured":"McGovern AS, Hamlin AS, Winter G. A review of the antimicrobial side of antidepressants and its putative implications on the gut microbiome. Aust NZJ Psychiatr. 2019;53:1151\u201366. https:\/\/doi.org\/10.1177\/0004867419877954.","journal-title":"Aust NZJ Psychiatr"},{"key":"274_CR105","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nature18848","volume":"535","author":"K Honda","year":"2016","unstructured":"Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature. 2016;535:75\u201384. https:\/\/doi.org\/10.1038\/nature18848 (PMID: 27383982).","journal-title":"Nature"},{"key":"274_CR106","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s13311-017-0585-0","volume":"15","author":"G Lach","year":"2018","unstructured":"Lach G, Schellekens H, Dinan TG, Cryan JF. Anxiety, depression, and the microbiome: a role for gut peptides. Neurotherapeutics. 2018;15:36\u201359. https:\/\/doi.org\/10.1007\/s13311-017-0585-0.","journal-title":"Neurotherapeutics"},{"key":"274_CR107","doi-asserted-by":"publisher","first-page":"12515","DOI":"10.1038\/s41598-019-48775-0","volume":"9","author":"M M\u00fcller","year":"2019","unstructured":"M\u00fcller M, Hern\u00e1ndez MAG, Goossens GH, Reijnders D, Holst JJ, Jocken JWE, et al. Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. Sci Rep. 2019;9:12515. https:\/\/doi.org\/10.1038\/s41598-019-48775-0.","journal-title":"Sci Rep"},{"key":"274_CR108","doi-asserted-by":"publisher","first-page":"43522","DOI":"10.1038\/srep43522","volume":"7","author":"R Aoki","year":"2017","unstructured":"Aoki R, Kamikado K, Suda W, Takii H, Mikami Y, Suganuma N, et al. A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. Sci Rep. 2017;7:43522. https:\/\/doi.org\/10.1038\/srep43522.","journal-title":"Sci Rep"},{"key":"274_CR109","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2337\/dc14-2690","volume":"38","author":"MC Simon","year":"2015","unstructured":"Simon MC, Strassburger K, Nowotny B, Kolb H, Nowotny P, Burkart V, et al. Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept. Diabetes Care. 2015;38:1827\u201334. https:\/\/doi.org\/10.2337\/dc14-2690.","journal-title":"Diabetes Care"},{"key":"274_CR110","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1128\/AEM.00739-08","volume":"74","author":"G Mandalari","year":"2008","unstructured":"Mandalari G, Nueno-Palop C, Bisignano G, Wickham MS, Narbad A. Potential prebiotic properties of almond (Amygdalus communis L.) seeds. Appl Environ Microbiol. 2008;74:4264\u201370. https:\/\/doi.org\/10.1128\/AEM.00739-08.","journal-title":"Appl Environ Microbiol."},{"key":"274_CR111","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3390\/nu10060661","volume":"10","author":"LL Wang","year":"2018","unstructured":"Wang LL, Wang Q, Hong Y, Ojo O, Jiang Q, Hou YY, et al. The effect of low-carbohydrate diet on glycemic control in patients with type 2 diabetes mellitus. Nutrients. 2018;10:661. https:\/\/doi.org\/10.3390\/nu10060661.","journal-title":"Nutrients"},{"key":"274_CR112","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.3390\/nu12103036","volume":"12","author":"M Ren","year":"2020","unstructured":"Ren M, Zhang H, Qi J, Hu A, Jiang Q, Hou Y, et al. An almond-based low carbohydrate diet improves depression and glycometabolism in patients with type 2 diabetes through modulating gut microbiota and glp-1: a randomized controlled trial. Nutrients. 2020;12:3036. https:\/\/doi.org\/10.3390\/nu12103036.","journal-title":"Nutrients"},{"key":"274_CR113","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jnutbio.2018.07.009","volume":"62","author":"GV Moreira","year":"2018","unstructured":"Moreira GV, Azevedo FF, Ribeiro LM, Santos A, Guadagnini D, Gama P, et al. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. J Nutr Biochem. 2018;62:143\u201354. https:\/\/doi.org\/10.1016\/j.jnutbio.2018.07.009.","journal-title":"J Nutr Biochem"},{"key":"274_CR114","doi-asserted-by":"publisher","first-page":"2947549","DOI":"10.1155\/2020\/2947549","volume":"2020","author":"N Zhang","year":"2020","unstructured":"Zhang N, Tao J, Gao L, Bi Y, Li P, Wang H, et al. Liraglutide attenuates nonalcoholic fatty liver disease by modulating gut microbiota in rats administered a high-fat diet. Biomed Res Int. 2020;2020:2947549. https:\/\/doi.org\/10.1155\/2020\/2947549.","journal-title":"Biomed Res Int"},{"key":"274_CR115","doi-asserted-by":"publisher","first-page":"e00009","DOI":"10.1002\/edm2.9","volume":"1","author":"Z Wang","year":"2017","unstructured":"Wang Z, Saha S, Van Horn S, Thomas E, Traini C, Sathe G, et al. Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects. Endocrinol Diab Metab. 2017;1:e00009. https:\/\/doi.org\/10.1002\/edm2.9.","journal-title":"Endocrinol Diab Metab"},{"key":"274_CR116","doi-asserted-by":"publisher","first-page":"e13738","DOI":"10.1111\/nmo.13738","volume":"32","author":"R O'Brien","year":"2020","unstructured":"O\u2019Brien R, O\u2019Malley D. The Glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome. Neurogastroenterol Motil. 2020;32:e13738. https:\/\/doi.org\/10.1111\/nmo.13738.","journal-title":"Neurogastroenterol Motil"},{"key":"274_CR117","doi-asserted-by":"publisher","first-page":"109908","DOI":"10.1016\/j.pnpbp.2020.109908","volume":"101","author":"SJ Millard","year":"2020","unstructured":"Millard SJ, Weston-Green K, Newell KA. The Wistar-Kyoto rat model of endogenous depression: a tool for exploring treatment resistance with an urgent need to focus on sex differences. Prog Neuropsychopharmacol Biol Psychiatr. 2020;101:109908. https:\/\/doi.org\/10.1016\/j.pnpbp.2020.109908.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatr"},{"key":"274_CR118","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.psyneuen.2018.05.010","volume":"94","author":"CD Moulton","year":"2018","unstructured":"Moulton CD, Hopkins CWP, Ismail K, Stahl D. Psychoneuroendocrinology repositioning of diabetes treatments for depressive symptoms\u202f: a systematic review and meta-analysis of clinical trials. Psychoneuroendocrinology. 2018;94:91\u2013103. https:\/\/doi.org\/10.1016\/j.psyneuen.2018.05.010.","journal-title":"Psychoneuroendocrinology"},{"key":"274_CR119","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.3390\/ijms21186969","volume":"21","author":"YS Woo","year":"2020","unstructured":"Woo YS, Lim HK, Wang SM, Bahk WM. Clinical evidence of antidepressant effects of insulin and anti-hyperglycemic agents and implications for the pathophysiology of depression-a literature review. Int J Mol Sci. 2020;21:6969. https:\/\/doi.org\/10.3390\/ijms21186969.","journal-title":"Int J Mol Sci"},{"key":"274_CR120","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jad.2019.05.044","volume":"257","author":"M Pozzi","year":"2019","unstructured":"Pozzi M, Mazhar F, Peeters GGAM, Vantaggiato C, Nobile M, Clementi E, et al. A systematic review of the antidepressant effects of glucagon-like peptide 1 ( GLP-1 ) functional agonists: Further link between metabolism and psychopathology Special Section on \u201cTranslational and Neuroscience Studies in Affective Disorders\u201d. Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. J Affect Disord. 2019;257:774\u20138. https:\/\/doi.org\/10.1016\/j.jad.2019.05.044.","journal-title":"J Affect Disord"},{"key":"274_CR121","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.pcd.2015.06.003","volume":"10","author":"CD Moulton","year":"2016","unstructured":"Moulton CD, Pickup JC, Amiel SA, Winkley K, Ismail K. Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study. Prim Care Diabetes. 2016;10:156\u20139. https:\/\/doi.org\/10.1016\/j.pcd.2015.06.003.","journal-title":"Prim Care Diabetes"},{"key":"274_CR122","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.euroneuro.2017.08.433","volume":"27","author":"RB Mansur","year":"2017","unstructured":"Mansur RB, Zugman A, Ahmed J, Cha DS, Subramaniapillai M, Lee Y, et al. Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. Eur Neuropsychopharmacol. 2017;27:1153\u201362. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.08.433.","journal-title":"Eur Neuropsychopharmacol"},{"key":"274_CR123","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/dom.12963","volume":"19","author":"PM O'Neil","year":"2017","unstructured":"O\u2019Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, et al. Satiety and clinical adiposity-liraglutide evidence in individuals with and without diabetes (scale) study groups. Neuropsychiatric safety with liraglutide 30 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017;19:1529\u201336. https:\/\/doi.org\/10.1111\/dom.12963.","journal-title":"Diabetes Obes Metab"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00274-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-021-00274-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00274-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T15:41:49Z","timestamp":1630683709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-021-00274-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["274"],"URL":"https:\/\/doi.org\/10.1007\/s43440-021-00274-8","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"31 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}